ImmunityBio (IBRX) Operating Margin (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Operating Margin of 157.88% for Q1 2026, up 23220.0% year-over-year from N/an in Q1 2025, and up 6.55% quarter-over-quarter from 168.95% in Q4 2025.
ImmunityBio (IBRX) Operating Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Operating Margin for 13 consecutive years, with 157.88% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 23220.0% year-over-year to 157.88%; the TTM figure through Mar 2026 stood at 185.41% (up 81841.0% YoY), while the FY2025 annual figure was 226.0%, up 210823.0% from the prior year.
- Operating Margin improved to 157.88% in Q1 2026 per IBRX's latest filing, from 168.95% in the prior quarter.
- Across five years, Operating Margin topped out at 157.88% in Q1 2026 and bottomed at 685514.29% in Q1 2022.
- Historically, Operating Margin has averaged 103232.55% across 5 years, with a median of 30994.44% in 2023.
- Annual changes were most pronounced in 2022 — Operating Margin slumped 62345385 bps — and 2023, when it soared 65451984 bps.
- ImmunityBio's Operating Margin stood at 116301.37% in 2022, then jumped by 47 bps to 61430.94% in 2023, then soared by 99 bps to 918.96% in 2024, then jumped by 82 bps to 168.95% in 2025, then increased by 7 bps to 157.88% in 2026.
- Business Quant data shows IBRX's Operating Margin at 157.88% in Q1 2026, 168.95% in Q4 2025, and 173.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -120.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -120.41% |
| Mar 31, 2026 | -157.88% |
| Dec 31, 2025 | -168.95% |
| Sep 30, 2025 | -173.51% |
| Jun 30, 2025 | -269.76% |
| Mar 31, 2025 | -390.08% |
| Dec 31, 2024 | -918.96% |
| Sep 30, 2024 | -1,314.33% |
| Jun 30, 2024 | -9,487.39% |
| Mar 31, 2024 | -237,990.00% |
| Dec 31, 2023 | -61,430.94% |
| Sep 30, 2023 | -97,726.83% |
| Jun 30, 2023 | -207,670.73% |
| Mar 31, 2023 | -30,994.44% |
| Dec 31, 2022 | -116,301.37% |
| Sep 30, 2022 | -76,952.54% |
| Jun 30, 2022 | -227,491.43% |
| Mar 31, 2022 | -685,514.29% |
| Dec 31, 2021 | -20,326.67% |
| Sep 30, 2021 | -119,448.48% |